METIS: Pivotal open-label randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC).
Brief description of study
The METIS trial is designed to investigate the efficacy of the NovoTTF-100M device in treating patients non-small cell lung cancer (NSCLC) with metastases to the brain. The eligible subjects must have 1 inoperable brain metastasis or 2-10 brain lesions and must be able to carry the NovoTTF-100M device. Subjects enrolled in the treatment arm of the study will wear the device for at least 18 hours a day, on average, and have study visits roughly every 2 months for 10-15 months.
For additional information regarding this clinical trial visit https://www.novocuretrial.com/metis/
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Lung cancer - non-small cell,Metastatic brain tumor
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
14 Jan 2020.
Study ID: 826343